If you or a loved one is taking Tysabri, you may have concerns about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing early symptoms—such as weakness, vision changes, or confusion—can be critical. Within the broader tradition of medical risk communication, this page provides a clear, evidence-based overview of how PML is diagnosed and what warning signs to watch for.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderate-to-severe active Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Massachusetts who have developed PML after Tysabri exposure, understanding the medical evidence and legal time limits is essential. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition presents with progressive neurological deficits, including cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation, and patients should continue to be monitored for at least six months after stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis and Crohn's disease but also impairs immune surveillance, creating an environment permissive for JC virus reactivation. The prescribing information includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Anti-JCV antibody positivity indicates prior exposure to the JC virus, and these patients have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug's mechanism of action—blocking lymphocyte trafficking to the brain—reduces the immune system's ability to control JC virus replication, allowing the virus to infect oligodendrocytes and cause demyelination. These risk factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program is designed to ensure that patients and providers are informed of this risk. However, the adequacy of these warnings in individual cases may be questioned if a patient developed PML without being adequately informed of the risk or if monitoring protocols were not properly followed.
For patients in Massachusetts who have developed PML after Tysabri exposure, legal claims may involve product liability or failure to warn theories. The statute of limitations for such claims in Massachusetts is generally three years from the date the injury was discovered or reasonably should have been discovered. Given that PML can present with subtle symptoms and may be diagnosed months after onset, the timeline between exposure and documented harm is critical. PML has been reported following discontinuation of Tysabri, and patients should continue monitoring for at least six months after stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This extended risk period may affect when the statute of limitations begins to run. Settlement considerations often include the severity of disability, medical expenses, lost income, and the strength of evidence regarding whether the patient was adequately warned of the PML risk. The risk of PML increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur earlier, particularly in patients with additional risk factors such as prior immunosuppressant use. The time from initial Tysabri infusion to PML diagnosis varies widely, and cases have been reported even after discontinuation of the drug. This variability underscores the importance of ongoing monitoring and prompt evaluation of any new neurological symptoms. For legal purposes, the date of diagnosis or the date when symptoms first became apparent is typically used to determine the start of the statute of limitations.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Massachusetts, the statute of limitations for product liability and failure to warn claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, this may be the date of diagnosis or when symptoms first became apparent.
Yes, PML has been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. Patients should continue to be monitored for at least six months after stopping treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.